| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | SCHEDULE 13G |
| 10 Nov 2026 | S-8 |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027 |
| 02 Oct 2026 |
Form 4: Houvras Yariv, CHIEF MEDICAL OFFICER
Granted 105,000 Stock Option (right to buy) |
| 02 Oct 2026 |
Form 3: Houvras Yariv, CHIEF MEDICAL OFFICER
No securities owned |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | S-8 |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 |
| 12 Jun 2026 |
Form 4: Bello Akintunde Olatokumbo, Director
Granted 5,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Shannon James Samuel, Director
Granted 5,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Curran Daniel J., Director
Granted 5,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Xu Yuan, Director
Granted 5,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Ross Robert W., Director
Granted 5,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Bonstein Sara, Director
Granted 5,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Brennan Aoife, Director
Granted 5,000 Stock Option (right to buy) |
| 12 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
In order to achieve a more equal balance of director membership among the three classes of the board of directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) in accordance with the Company’s Restated Certificate of Incorpor... |
Loading...